Syndrome News and Research

RSS
New study assesses COVID-19 risk among UK healthcare workers

New study assesses COVID-19 risk among UK healthcare workers

NLRP3 inflammasome inhibitors may help treat early COVID-19, says study

NLRP3 inflammasome inhibitors may help treat early COVID-19, says study

South African SARS-CoV-2 variant partly resistant to neutralization by mRNA vaccine, says study

South African SARS-CoV-2 variant partly resistant to neutralization by mRNA vaccine, says study

A missing protein explains the appearance of tumor cells in people with Mulibrey syndrome

A missing protein explains the appearance of tumor cells in people with Mulibrey syndrome

Repurposed drugs show antiviral SARS-CoV-2 E channel blocking activity, finds study

Repurposed drugs show antiviral SARS-CoV-2 E channel blocking activity, finds study

Researchers develop new tool for predicting the effects of SARS-CoV-2 missense variants

Researchers develop new tool for predicting the effects of SARS-CoV-2 missense variants

Structure of SARS-CoV-2 envelope protein-epithelial cell junction protein complex explains virulence

Structure of SARS-CoV-2 envelope protein-epithelial cell junction protein complex explains virulence

Learning to live again: A Lazarus tale from the Covid front lines

Learning to live again: A Lazarus tale from the Covid front lines

Inhalable nanobody shows potent anti-SARS-CoV-2 activity in vivo

Inhalable nanobody shows potent anti-SARS-CoV-2 activity in vivo

What is the impact of demographics and air quality on COVID-19 mortality?

What is the impact of demographics and air quality on COVID-19 mortality?

Is one dose of Pfizer-BioNTech mRNA vaccine for COVID-19 convalescents sufficient?

Is one dose of Pfizer-BioNTech mRNA vaccine for COVID-19 convalescents sufficient?

Mandatory public health measures to combat COVID-19 are more effective, says study

Mandatory public health measures to combat COVID-19 are more effective, says study

Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

Pre-existing cross-reactive HCoV antibodies could protect against SARS-CoV-2

Pre-existing cross-reactive HCoV antibodies could protect against SARS-CoV-2

Microbes could predict fatal outcomes in ventilated COVID-19 patients

Microbes could predict fatal outcomes in ventilated COVID-19 patients

Study finds link between Googling symptoms and COVID-19 cases

Study finds link between Googling symptoms and COVID-19 cases

CRISPR screen identifies clinically approved immunosuppressants that could treat coronavirus infections

CRISPR screen identifies clinically approved immunosuppressants that could treat coronavirus infections

Study pinpoints potential transmission advantage of SARS-CoV-2 variant B.1.1.7

Study pinpoints potential transmission advantage of SARS-CoV-2 variant B.1.1.7

UC San Diego receives $33 million from NIH for five COVID-19 diagnostic projects

UC San Diego receives $33 million from NIH for five COVID-19 diagnostic projects

SARS-CoV-2 ORF7a mutation limits host immune suppression, finds study

SARS-CoV-2 ORF7a mutation limits host immune suppression, finds study